This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Only fifteen days after saying it was searching for strategic alternatives, iTeo...
Plus, news about Advanz, Alvotech and GeNeuro: Veru’s obesity drug generally...
Headed into the biggest oncology research and development confab of the year, an...
Today on Post-Hoc Live, we’re going to take a deep dive into Founding Editor Joh...
A Boston biotech with self-replicating mRNA technology has shared early data fro...
Headed into the biggest oncology research and development confab of the year, on...
InflaRx is to cease work on its intravenous complement inhibitor Gohibic for the...
Hetero Labs could launch its generic sleep disorder drug as early as 2040 under ...
Novartis won a bidding war against a fellow large drugmaker to acquire Regulus T...
FDA Commissioner Marty Makary, newly minted CBER chief Vinay Prasad and Principa...
Boundless Bio has hit the reset button in the face of toxicity issues, nixing on...
The FDA has rejected Savara’s application for its rare lung disease candidate ov...
Canadian cell therapy biotech Sernova said Sunday that its board chairman Ross H...
Boundless Bio has hit the reset button in the face of toxicity issues, nixing on...
Rocket Pharmaceuticals said Tuesday morning that a patient in its gene therapy t...